US20130165404A1 - Hybrid cooperative complexes of hyaluronic acid - Google Patents
Hybrid cooperative complexes of hyaluronic acid Download PDFInfo
- Publication number
- US20130165404A1 US20130165404A1 US13/820,838 US201113820838A US2013165404A1 US 20130165404 A1 US20130165404 A1 US 20130165404A1 US 201113820838 A US201113820838 A US 201113820838A US 2013165404 A1 US2013165404 A1 US 2013165404A1
- Authority
- US
- United States
- Prior art keywords
- complexes
- patients
- complexes according
- hybrid
- hybrid cooperative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
- C08L3/02—Starch; Degradation products thereof, e.g. dextrin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/02—Dextran; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Definitions
- the present invention relates to the field of products based on hyaluronic acid.
- Hyaluronic acid is a negatively charged straight-chain polysaccharide, made up of a repetition of n disaccharide units (-4GlcUA ⁇ 1-3GlcNAc ⁇ 1-), in which D-glucuronic acid (GlcUA) and N-acetyl-D-glucosamine (GlcNAc) are joined with alternating ⁇ -1,3 and ⁇ -1,4 glycosidic bonds.
- HA is a highly water-soluble polysaccharide and solutions of HA display a non-Newtonian type of viscoelastic behaviour. These properties depend on the molecular weight (and therefore, as HA is a linear polymer, on the length of the chain), the concentration, the pH and the ionic strength.
- HA Owing to its biological properties and functions, HA has high added value (its commercial value greatly exceeds that of the other natural polysaccharides), with applications that range from the medical sector to cosmeceuticals and nutraceuticals. Its viscoelastic properties, coupled with the complete absence of toxicity or immunogenicity (the structure of HA is always the same in all living organisms in which it is present), have led to varied and extensive applications.
- the performance depends on the molecular weight of the HA.
- the average molecular weight of HA and the polydispersity index Mw/Mn (which measures the width of the curve of molecular weight distribution, where Mn is the number-average molecular weight, defined as the total weight of all the polymer molecules in a sample divided by the total number of molecules, and Mw is the weight-average molecular weight, which takes into account the varying mass of the molecules present) must be the gold standards to be considered when developing production processes for HA and strategies for application.
- L-HA low molecular weight HA
- H-HA high molecular weight HA
- the present invention describes cooperative hybrid complexes between L-HA and H-HA, designated with the acronym L/H-HA, their characteristics, the production process thereof and use thereof in the area of medicine, cosmetics and foodstuffs.
- Weak forces such as hydrogen bonds or hydrophobic interactions, can give rise to very stable interactions between molecules, if these are of the cooperative type.
- Cooperativeness develops when it is possible for multiple bonds to form between the molecules, and being weak, they break randomly thereafter, but can immediately reform owing to the existence of intact vicinal bonds, which maintain the structural components of the bond at a distance useful for its reformation.
- the molecules of HA in solution are characterized by cooperative phenomena of interaction based on formation of hydrophobic bonds and interchain hydrogen bonds, and the cooperativeness of these interactions depends on the length and therefore on the molecular weight of the chains.
- the long chains of H-HA give stable interactions between them, which involve all the molecules present in solution, giving rise to a three-dimensional network, whereas molecules of L-HA give interactions that are less stable, leading to systems of aggregation that do not simultaneously involve all the molecules present, which instead interact in clusters.
- This differing mode of aggregation of H-HA and L-HA in solution is responsible for the large differences in rheological behaviour, such as for example the viscosity of solutions of HA, which is a very important property for numerous applications, especially in the medical field.
- solutions of stable L/H-HA cooperative hybrids according to the invention are characterized by viscosities that do not change over time and that are notably lower than before the thermal cycle.
- the molecular weight of HA used in constructing L/H-HA hybrid systems critically determines their rheological characteristics; the greater the difference in molecular weight between the L-HA and H-HA used, the greater, at equal concentration, is the decrease in viscosity of the hybrid system relative to that of the H-HA.
- Cooperative hybrid L/H-HA complexes characterized by a decrease in viscosity, can be obtained if the molecular weight of the L-HA is between 1 ⁇ 10 4 and 1 ⁇ 10 6 Da and that of the H-HA is given by the formula MW H-HA ⁇ MW L-HA /0.9.
- the complexes according to the invention normally have a viscosity from 1.1 to 200-fold less than that of a solution containing the H-HA hyaluronic acid alone used for forming the complex
- the thermal profile that leads to the formation of cooperative hybrid L/H-HA systems starting from solutions containing L-HA and H-HA envisages that the solution is first heated to temperatures between 80 and 160° C., preferably between 100 and 120° C. and then cooled rapidly to room temperature.
- the L/H-HA hybrid systems thus obtained are stable over time, attesting to maintenance of their rheological characteristics.
- the solutions of L/H-HA hybrid complexes according to the present invention can easily be obtained by mixing aqueous solutions of H-HA and L-HA of desired molecular weight and submitting the resultant solution to the thermal cycle indicated above; preferably the concentration of the solution of L-HA is between 0.01 and 50% w/w while that of the solution of H-HA is between 0.01 and 10% w/w.
- Cooperative hybrid L/H-HA complexes in the solid state can be obtained from solutions containing them in various ways:
- Cooperative hybrid complexes similar to those described above, characterized by low values of dynamic viscosity, can moreover be obtained by high-temperature thermal treatment of aqueous solutions of H-HA with low molecular weight polysaccharides, such as chondroitin, chondroitin sulphate, dextrins, cyclodextrins, dextrans.
- low molecular weight polysaccharides such as chondroitin, chondroitin sulphate, dextrins, cyclodextrins, dextrans.
- the cooperative hybrid L/H-HA complexes are, because of their rheological characteristics, of considerable interest in some biomedical applications, for example: biorevitalization of the skin by intradermal injections of HA; techniques of viscosupplementation for resolving pathological situations connected with inflammatory disorders of the joints; intra-bladder treatment of cystitis; treatment of vaginal inflammatory diseases; treatment of alveolar diseases; treatment of oral diseases.
- the cooperative hybrid L/H-HA complexes behave as systems for slow release of L-HA and H-HA, because the chemical complexity of the microenvironment, characterized by the presence of other species in solution and the enormous surfaces of the cellular structures, permit gradual resolution of the intermolecular interactions that characterize the complex, making both L-HA and H-HA available in context ab initio, molecular species that in vivo have differentiated roles, L-HA that of signalling by interaction with receptors present on the cell surfaces and H-HA as a fundamental constituent of the extracellular matrix.
- Non-limiting examples are given below, describing the production, characteristics and use of the cooperative hybrid L/H-HA complexes.
- H-HA MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5
- L-HA MW 3.3 ⁇ 10 4 Da; Mw/Mn 1.8
- MW and polydispersity index Mw/Mn are determined using a size-exclusion chromatography system equipped with a multidetector, consisting of a four-bridge viscosimeter, a refractometer, a right angle light scattering detector (RALS) and a low angle light scattering detector (LALS), patented by the American group Viscotek (www.viscotek.com).
- the signal measured with the LALS is proportional to the molecular weight and the concentration, that measured with the viscosimetric detector is proportional to the sample concentration and the intrinsic viscosity, while the refractometer provides measurement of the concentration.
- Table 1 Measurement of the dynamic viscosity of solutions with a concentration of 1% w/v of L-HA (MW 3.3 ⁇ 10 4 Da; Mw/Mn 1.8) and H-HA (MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5) and of the corresponding stable cooperative L/H-HA complexes with a concentration of 1% w/v and L-HA/H-HA ratio of 1:1 w/w.
- the thermal treatment cycle in autoclave envisages a heating phase in 10 min from 25° C. to T max , remaining at T max for a specified time and a cooling phase from T max to 25° C. in 10 min.
- the measurements of ⁇ are taken immediately after the thermal treatment.
- Cooperative hybrid L/H-HA complexes of different composition are prepared by dissolving H-HA (MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5) and L-HA (MW 3.3 ⁇ 10 4 Da; Mw/Mn 1.8) in 100 mL of water, as shown in Table 2.
- the resultant solutions are submitted to the following thermal cycle in autoclave: from 25° C. to 120° C. in 10 min, for 10 min at 120° C., from 120° C. to 25° C. in 10 min.
- the dynamic viscosity of the samples, the MW and the polydispersity index Mw/Mn of L-HA, H-HA and L/H-HA are determined as described in example 1.
- the data in Table 2 demonstrate the dependence of the viscosity of L/H-HA cooperative complexes on the L-HA/H-HA ratio: the higher the ratio, the lower the viscosity.
- Table 2 Measurement of the dynamic viscosity ⁇ of cooperative hybrid L/H-HA complexes with different L-HA/H-HA ratio.
- concentration of H-HA MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5
- L-HA MW 3.3 ⁇ 10 4 Da; Mw/Mn 1.8
- the thermal treatment cycle in autoclave envisages a heating phase of 10 min from 25° C. to T max , remaining at T max for a specified time and a cooling phase from T max to 25° C. in 10 min.
- the measurements of ⁇ are taken immediately after the thermal treatment.
- Aqueous solutions of H-HA (MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5), L-HA (MW 3.3 ⁇ 10 4 Da; Mw/Mn 1.8) and L-HA (MW 2.2 ⁇ 10 5 Da; Mw/Mn 1.7) are prepared at 2% w/v in distilled water, which are used for preparing the various solutions given in Table 3.
- the resultant solutions are submitted to the following thermal cycle in autoclave: from 25 to 120° C. in 10 min, for 10 min at 120° C., from 120 to 25° C. in 10 min.
- the dynamic viscosity ⁇ of the samples, the MW and the polydispersity index Mw/Mn of L-HA, H-HA and L/H-HA are determined as described in example 1.
- Table 3 Measurement of the dynamic viscosity ⁇ of cooperative hybrid L/H-HA complexes with L-HA/H-HA ratio of 1 w/w, constructed with L-HA of different MW.
- Aqueous solutions of H-HA (MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5), L-HA (MW 3.3 ⁇ 10 4 Da; Mw/Mn 1.8) and L-HA (MW 2.2 ⁇ 10 5 Da; Mw/Mn 1.7) are prepared at 2% w/v in distilled water, which are used for preparing the various solutions given in the table.
- the resultant solutions are submitted to the following thermal cycle in autoclave: from 25 to 120° C. in 10 min, for 10 min at 120° C., from 120 to 25° C. in 10 min.
- Aqueous solutions of H-HA (MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5), L-HA (MW 3.3 ⁇ 10 4 Da; Mw/Mn 1.8) and L-HA (MW 2.2 ⁇ 10 5 Da; Mw/Mn 1.7) are prepared at 2% w/v in distilled water, which are used for preparing the various solutions given in Table 4.
- Half of the resultant solutions are maintained at temperature and the other half are first submitted to the following thermal cycle in autoclave: from 25 to 120° C. in 10 min, for 10 min at 120° C., from 120 to 25° C. in 10 min and are then maintained at room temperature.
- the dynamic viscosity ⁇ is measured over time, for both series of samples.
- the MW, the polydispersity index Mw/Mn of L-HA, H-HA and L/H-HA and the dynamic viscosity ⁇ of the samples are determined as described in example 1.
- Table 4 Kinetics of the dynamic viscosity ⁇ of cooperative hybrid L/H-HA complexes with L-HA/H-HA ratio of 1 w/w, constructed with L-HA of different MW.
- Aqueous solutions of H-HA (MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5), L-HA (MW 3.3 ⁇ 10 4 Da; Mw/Mn 1.8) and L-HA (MW 2.2 ⁇ 10 5 Da; Mw/Mn 1.7) are prepared at 2% w/v in distilled water, which are used for preparing the various solutions given in the table.
- Half of the resultant solutions are maintained at temperature and half are first submitted to the following thermal cycle in autoclave: from 25 to 120° C. in 10 min, for 10 min at 120° C., from 120 to 25° C. in 10 min and are then maintained at room temperature.
- the aqueous solution of the cooperative hybrid L/H-HA complex obtained as described in example 1 with a thermal cycle that envisages exposure to a T max of 120° C. for 10 min, is treated with 2 volumes of anhydrous ethanol, added slowly and with stirring. A white pulverulent precipitate is obtained, which sediments rapidly and can be dried under vacuum with heating. The process leads to formation of a white dry powder, at a yield of 99% relative to the theoretical value.
- the cooperative hybrid L/H-HA complex in powder if dissolved in water at a concentration of 1% w/w, gives a solution that has the same value of dynamic viscosity ⁇ as the solution precipitated initially.
- the aqueous solution of the cooperative hybrid L/H-HA complex, obtained as described in example 1 with a thermal cycle that envisages exposure to a T max of 120° C. for 10 min is lyophilized.
- a spongy mass is obtained, which is easily transformed into a white powder by mechanical treatment.
- the yield of lyophilized powder coincides with the theoretical value.
- the cooperative hybrid L/H-HA complex lyophilized in powder if dissolved in water at a concentration 1% w/w, gives a solution that has the same value of dynamic viscosity ⁇ as the solution precipitated initially.
- Aqueous solutions of H-HA (MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5), chondroitin (C; MW 6.6 ⁇ 10 4 Da; Mw/Mn 1.4) and chondroitin sulphate (CS; MW 3.8 ⁇ 10 4 Da; Mw/Mn 1.4) are prepared at 2% w/v in distilled water, which are used for preparing the various solutions given in Table 5.
- the resultant solutions are submitted to the following thermal cycle in autoclave: from 25 to 120° C. in 10 min, for 10 min at 120° C., from 120 to 25° C. in 10 min.
- the dynamic viscosity ⁇ of the samples, the MW and the polydispersity index Mw/Mn of L-HA, H-HA and L/H-HA are determined as described in example 1.
- Table 5 Measurement of the dynamic viscosity ⁇ of cooperative hybrid C/H-HA and CS/H-HA complexes.
- Aqueous solutions of H-HA (MW 1.4 ⁇ 10 6 Da; Mw/Mn 1.5), C (MW 6.6 ⁇ 10 4 Da; Mw/Mn 1.4) and CS (MW 3.8 ⁇ 10 4 Da; Mw/Mn 1.4) are prepared at 2% w/v in distilled water, which are used for preparing the various solutions given in the table.
- the resultant solutions are submitted to the following thermal cycle in autoclave: from 25 to 120° C. in 10 min, for 10 min at 120° C., from 120 to 25° C. in 10 min.
- 4g of the cooperative hybrid complex obtained as described in example 1 is dissolved in 100 mL of saline, heating at 120° C. for 10 min, and then drying the complex by lyophilization, as described in example 5.
- the hyaluronic acid used is of pharmaceutical grade for injection and all the manipulations are carried out in conditions that guarantee sterility and apyrogenicity of the solution.
- the solution containing 40 mg/mL of L/H-HA complexes is introduced into 1 mL syringes fitted with a gauge 30 needle.
- the treatment of biorevitalization of the face is conducted on 10 informed volunteers, who have obvious signs of cutaneous ageing of the face.
- the experimental design envisages that each subject undergoes an identical treatment of biorevitalization by subcutaneous microinjection on the right side of the face with the formulation of the invention (1 mL) and on the left side with a primary product already marketed (1 mL).
- the results obtained, objectivized instrumentally, demonstrate the superiority of the treatment with the stable cooperative L/H-HA complex, both in terms of quality and duration of the treatment.
- 4g of the cooperative hybrid complex obtained as described in example 1 is dissolved in 100 mL of saline, heating at 120° C. for 10 min, and then drying the complex by lyophilization, as described in example 5.
- the hyaluronic acid used is of pharmaceutical grade for injection and all the manipulations are carried out in conditions that guarantee sterility and apyrogenicity of the solution.
- the solution containing 40 mg/mL of L/H-HA complexes is introduced into 1 mL syringes fitted with a gauge 30 needle.
- the viscosupplementation treatment is conducted on 5 informed volunteers, with a bilateral knee disorder, the therapeutic indication being infiltration of hyaluronic acid in the joint.
- the experimental design envisages that each subject receives identical treatment of viscosupplementation in the right joint with the formulation of the invention (1 mL) and in the left joint with a primary product already marketed (1 mL).
- the results obtained, objectivized instrumentally, demonstrate the superiority of the treatment with the stable cooperative L/H-HA complex, both in terms of rapid reduction of pain and efficacy of resolution of the pathological condition.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2010A001635A IT1402382B1 (it) | 2010-09-09 | 2010-09-09 | Complessi cooperativi ibridi di acido ialuronico |
ITMI2010A001635 | 2010-09-09 | ||
PCT/EP2011/065633 WO2012032151A2 (en) | 2010-09-09 | 2011-09-09 | Hybrid cooperative complexes of hyaluronic acid |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/065633 A-371-Of-International WO2012032151A2 (en) | 2010-09-09 | 2011-09-09 | Hybrid cooperative complexes of hyaluronic acid |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/974,657 Continuation US10266611B2 (en) | 2010-09-09 | 2015-12-18 | Hybrid cooperative complexes of hyaluronic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130165404A1 true US20130165404A1 (en) | 2013-06-27 |
Family
ID=43528358
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/820,838 Abandoned US20130165404A1 (en) | 2010-09-09 | 2011-09-09 | Hybrid cooperative complexes of hyaluronic acid |
US14/974,657 Active 2032-05-02 US10266611B2 (en) | 2010-09-09 | 2015-12-18 | Hybrid cooperative complexes of hyaluronic acid |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/974,657 Active 2032-05-02 US10266611B2 (en) | 2010-09-09 | 2015-12-18 | Hybrid cooperative complexes of hyaluronic acid |
Country Status (11)
Country | Link |
---|---|
US (2) | US20130165404A1 (de) |
EP (1) | EP2614090B2 (de) |
CA (1) | CA2810742C (de) |
DK (1) | DK2614090T3 (de) |
ES (1) | ES2613067T3 (de) |
HU (1) | HUE031242T2 (de) |
IT (1) | IT1402382B1 (de) |
LT (1) | LT2614090T (de) |
PL (1) | PL2614090T3 (de) |
PT (1) | PT2614090T (de) |
WO (1) | WO2012032151A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980866B2 (en) | 2011-11-24 | 2015-03-17 | Opko Lab Europe, S.L. | Complex obtained from hyaluronic acid or a salt thereof and chondroitin sulphate mixtures |
CN104592702A (zh) * | 2014-12-26 | 2015-05-06 | 四川大学 | 可自愈合的有机物/无机纳米粒子杂化材料及其制备方法 |
CN114828902A (zh) * | 2019-12-17 | 2022-07-29 | 阿尔特刚股份有限公司 | 用于皮肤-美容的可注射的透明质酸混合物 |
US20240002551A1 (en) * | 2021-07-30 | 2024-01-04 | Meyer Bio-medicine Co., Ltd. | Sodium hyaluronate with full molecular weight distribution (mwd), and preparation method and use thereof |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20120896A1 (it) | 2012-05-23 | 2013-11-24 | Bongulielmi Reto | Condroitina per uso in medicina |
ITUB20152542A1 (it) * | 2015-07-28 | 2017-01-28 | Altergon Sa | Formulati oftalmici a base di complessi cooperativi di acido ialuronico a basso e alto peso molecolare |
CN107802597B (zh) * | 2017-12-08 | 2020-07-31 | 北京诺康达医药科技股份有限公司 | 一种玻璃酸钠组合物及其制备方法和应用 |
IT201900006250A1 (it) | 2019-04-23 | 2020-10-23 | Fidia Farm Spa | Medicazione per il trattamento della cute lesa |
IT201800010415A1 (it) * | 2018-11-19 | 2020-05-19 | Innate S R L | Composizione iniettabile comprendente acido ialuronico e trealosio e uso della detta composizione. |
IT201900021693A1 (it) | 2019-11-20 | 2021-05-20 | Bmg Pharma S P A | Derivati butirrati o butirrati e formiati dell’acido ialuronico reticolati e loro procedimento di reticolazione |
IT201900024214A1 (it) | 2019-12-17 | 2021-06-17 | Altergon Sa | Sostituti del liquido sinoviale |
CN113244384A (zh) | 2020-02-11 | 2021-08-13 | 阿尔特刚股份有限公司 | 抗病毒组合物 |
IT202000002641A1 (it) | 2020-02-11 | 2021-08-11 | Altergon Sa | Composizioni antivirali |
IT202000002866A1 (it) | 2020-02-13 | 2021-08-13 | Altergon Sa | Composizioni antivirali |
IT202000029288A1 (it) | 2020-12-01 | 2022-06-01 | Altergon Sa | Sali di microbiocidi biguanidinici con glicosamminoglicani |
IT202100027047A1 (it) | 2021-10-21 | 2023-04-21 | The Wave Innovation Group Srls | Composizione eterogenea a fasi stratificate di acido ialuronico e suo uso intrarticolare |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4920104A (en) * | 1988-05-16 | 1990-04-24 | Medchem Products, Inc. | Sodium hyaluronate composition |
US6891035B2 (en) * | 2001-06-29 | 2005-05-10 | Biovitrum Ab | Process for bulk autoclaving |
US20070141101A1 (en) * | 2003-04-10 | 2007-06-21 | The Trustees Of Boston University | Method for stimulating angiogenesis and wound healing |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
CA2060223C (en) | 1991-02-12 | 1999-07-20 | Clarence C. Lee | Injectable medical lubricating fluid composition and method of use |
US5621093A (en) | 1995-06-06 | 1997-04-15 | Anika Research, Inc. | Steam-sterilizing solid hyaluronic acid |
US20030104601A1 (en) † | 1999-04-01 | 2003-06-05 | Deangelis Paul L. | Chondroitin synthase gene and methods of making and using same |
US6482401B1 (en) † | 1998-12-23 | 2002-11-19 | Naturopathic Laboratories International, Inc. | Composition for the relief of joint pain and myofascial pain and method of preparing same |
DE60034667T2 (de) | 1999-02-01 | 2008-03-13 | Dermal Research Laboratories, Inc. | Pharmazeutische zusammensetzung aus komplexen kohlenhydraten und deren anwendung |
FR2861734B1 (fr) * | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
WO2006043965A1 (en) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
WO2006058109A1 (en) | 2004-11-23 | 2006-06-01 | Alcon, Inc. | Triple natural polymer viscoelastic composition |
US20070010481A1 (en) | 2005-07-07 | 2007-01-11 | Matrix Biology Institute | Solid State Irradiation of Hyaluronan-Based Solid Preparations, Its Derivatives And Mixtures In An Unsaturated Gaseous Atmosphere And Their Use |
EP1940468B1 (de) | 2005-09-07 | 2017-11-15 | AMO Regional Holdings | Bimodale hyaluronat-lösung |
PT2026821E (pt) * | 2006-05-11 | 2009-12-09 | Robert John Petrella | Misturas binárias de ácido hialurónico e uso terapêutico das mesmas |
ITMI20061030A1 (it) | 2006-05-26 | 2007-11-27 | Altergon Sa | Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica |
DE102006060953A1 (de) | 2006-12-12 | 2008-08-07 | Farco-Pharma Gmbh | Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes |
FR2918276B1 (fr) | 2007-07-02 | 2010-01-22 | Anteis Sa | "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires" |
US8735373B2 (en) * | 2008-05-13 | 2014-05-27 | Apharm S.R.L. | Glycosaminoglycan oral use and compositions |
US20100098794A1 (en) * | 2008-10-17 | 2010-04-22 | Armand Gerard | Topical anti-wrinkle and anti-aging moisturizing cream |
FR2938187B1 (fr) * | 2008-11-07 | 2012-08-17 | Anteis Sa | Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur |
IT1404145B1 (it) † | 2010-12-27 | 2013-11-15 | Altergon Sa | Composizioni di acido ialuronico stabilizzate verso l'azione di degradazione del calore o degli enzimi |
-
2010
- 2010-09-09 IT ITMI2010A001635A patent/IT1402382B1/it active
-
2011
- 2011-09-09 EP EP11769800.1A patent/EP2614090B2/de active Active
- 2011-09-09 HU HUE11769800A patent/HUE031242T2/en unknown
- 2011-09-09 WO PCT/EP2011/065633 patent/WO2012032151A2/en active Application Filing
- 2011-09-09 PT PT117698001T patent/PT2614090T/pt unknown
- 2011-09-09 CA CA2810742A patent/CA2810742C/en active Active
- 2011-09-09 ES ES11769800.1T patent/ES2613067T3/es active Active
- 2011-09-09 DK DK11769800.1T patent/DK2614090T3/da active
- 2011-09-09 US US13/820,838 patent/US20130165404A1/en not_active Abandoned
- 2011-09-09 PL PL11769800T patent/PL2614090T3/pl unknown
- 2011-09-09 LT LTEP11769800.1T patent/LT2614090T/lt unknown
-
2015
- 2015-12-18 US US14/974,657 patent/US10266611B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4920104A (en) * | 1988-05-16 | 1990-04-24 | Medchem Products, Inc. | Sodium hyaluronate composition |
US6891035B2 (en) * | 2001-06-29 | 2005-05-10 | Biovitrum Ab | Process for bulk autoclaving |
US20070141101A1 (en) * | 2003-04-10 | 2007-06-21 | The Trustees Of Boston University | Method for stimulating angiogenesis and wound healing |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980866B2 (en) | 2011-11-24 | 2015-03-17 | Opko Lab Europe, S.L. | Complex obtained from hyaluronic acid or a salt thereof and chondroitin sulphate mixtures |
CN104592702A (zh) * | 2014-12-26 | 2015-05-06 | 四川大学 | 可自愈合的有机物/无机纳米粒子杂化材料及其制备方法 |
CN114828902A (zh) * | 2019-12-17 | 2022-07-29 | 阿尔特刚股份有限公司 | 用于皮肤-美容的可注射的透明质酸混合物 |
US20240002551A1 (en) * | 2021-07-30 | 2024-01-04 | Meyer Bio-medicine Co., Ltd. | Sodium hyaluronate with full molecular weight distribution (mwd), and preparation method and use thereof |
US11976139B2 (en) * | 2021-07-30 | 2024-05-07 | Meyer Bio-medicine Co., Ltd. | Sodium hyaluronate with full molecular weight distribution (MWD), and preparation method and use thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2613067T3 (es) | 2017-05-22 |
LT2614090T (lt) | 2017-01-25 |
DK2614090T3 (da) | 2017-01-02 |
ITMI20101635A1 (it) | 2012-03-10 |
WO2012032151A3 (en) | 2012-08-30 |
IT1402382B1 (it) | 2013-09-04 |
EP2614090B2 (de) | 2024-04-24 |
US10266611B2 (en) | 2019-04-23 |
WO2012032151A2 (en) | 2012-03-15 |
CA2810742C (en) | 2018-08-21 |
CN103119068A (zh) | 2013-05-22 |
PL2614090T3 (pl) | 2017-03-31 |
EP2614090B1 (de) | 2016-11-02 |
PT2614090T (pt) | 2017-02-08 |
HUE031242T2 (en) | 2017-07-28 |
CA2810742A1 (en) | 2012-03-15 |
US20160102154A1 (en) | 2016-04-14 |
EP2614090A2 (de) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10266611B2 (en) | Hybrid cooperative complexes of hyaluronic acid | |
Leone et al. | Enriched Gellan Gum hydrogel as visco-supplement | |
Maiz-Fernández et al. | 3D printable self-healing hyaluronic acid/chitosan polycomplex hydrogels with drug release capability | |
Lejardi et al. | Novel hydrogels of chitosan and poly (vinyl alcohol)-g-glycolic acid copolymer with enhanced rheological properties | |
US9062129B2 (en) | Hyaluronic acid esters, their preparation and use in dermatology | |
Finelli et al. | A new viscosupplement based on partially hydrophobic hyaluronic acid: a comparative study | |
Mayol et al. | Effect of hyaluronic acid on the thermogelation and biocompatibility of its blends with methyl cellulose | |
Nyström et al. | Characterization of polyelectrolyte features in polysaccharide systems and mucin | |
Picotti et al. | Hyaluronic acid lipoate: synthesis and physicochemical properties | |
Wu et al. | Water soluble complexes of chitosan‐g‐MPEG and hyaluronic acid | |
EP2922581B1 (de) | Mukoadhäsive zusammensetzungen mit hyaluronsäure und chitosan zur topischen anwendung | |
JP2009516765A (ja) | 新規ヒアルロン酸誘導体、その製造方法及びその使用 | |
ITMI20072237A1 (it) | Esteri misti butirrico-formico di polisaccaridi acidi, loro preparazione ed uso come dermocosmetici | |
Ren et al. | Injectable supramolecular hydrogels based on host–guest interactions with cell encapsulation capabilities | |
Montanari et al. | Halting hyaluronidase activity with hyaluronan-based nanohydrogels: Development of versatile injectable formulations | |
Wu et al. | Injectable chitosan/dextran-polylactide/glycerophosphate hydrogels and their biodegradation | |
Mousavi et al. | Partial sulfation of gellan gum produces cytocompatible, body temperature-responsive hydrogels | |
US11359030B2 (en) | Method for preparing low molecular weight hyaluronic acid | |
CN105873955A (zh) | 富氘透明质酸 | |
CN103119068B (zh) | 透明质酸的杂化协同复合物 | |
CN106573013B (zh) | 用于治疗关节炎的包含石莼多糖的粘性补充剂组合物 | |
WO2018079812A1 (ja) | ゲル組成物及びその製造方法 | |
RU2750000C1 (ru) | Способ получения модифицированного гиалуронана и его применение в медицине, в том числе при эндопротезировании | |
Zhao | Synthesis and characterization of oxidized alginate hydrogels as in vitro model for breast cancer | |
KR20220070499A (ko) | 글루콘산 아연 및 히알루론산 에스테르 기반 하이드로겔 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALTERGON S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DE ROSA, MARIO;D'AGOSTINO, ANTONELLA;LA GATTA, ANNALISA;AND OTHERS;REEL/FRAME:029923/0996 Effective date: 20130212 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |